摘要
目的探讨顺铂(DDP)联合表阿霉素(E-ADM)术前化疗方式对宫颈癌切除术患者手术疗效及预后的影响。方法回顾性分析2014年8月至2016年8月经郑州大学第三附属医收治的96例行宫颈癌切除术患者病历资料,按术前化疗差异分作实施紫杉醇(TAX)+DDP髂内动脉灌注化疗的对照组(n=36例)及于术前实施DDP+E-ADM髂内动脉灌注化疗的观察组(n=60例),随访至2019年12月,比较两组手术疗效及预后。结果经术前化疗并行宫颈癌切除术后,截至2019年12月,获得随访人数92例,随访率95.83%,于治疗3年内死亡8例,3年以上存活率为91.67%;观察组客观缓解率(ORR)为48.33%,相比于对照组的41.67%,差异无统计学意义(P>0.05);观察组预后不良反应中Ⅰ+Ⅱ级骨髓抑制、胃肠道反应及Ⅰ~Ⅳ级肾脏毒性发生率相较于对照组而言均更低(P<0.05)。结论于宫颈癌切除术前实施DDP+E-ADM或TAX+DDP术前化疗,所获得手术疗效一致,但DDP+E-ADM整体预后情况较好。
【Objective】To investigate the effect of cisplatin(DDP)combined with epirubicin(E-ADM)preoperative chemotherapy on the surgical efficacy and prognosis of patients undergoing cervical cancer resection.【Methods】Medical records of 96 patients undergoing cervical cancer resection in our hospital from August 2014 to August 2016 were retrospectively analyzed.According to the differences in preoperative chemotherapy,patients were divided into the control group for the implementation of paclitaxel(TAX)+DDP internal iliac artery infusion chemotherapy(n=36 cases)and the observation group(n=60 cases)who received DDP+E-ADM internal iliac arterial infusion chemotherapy before surgery.The patients were followed up to December 2019,and the surgical efficacy and prognosis of the two groups were compared.【Results】After preoperative chemotherapy and cervical cancer resection,as of December 2019,92 cases were followed up,with a follow-up rate of 95.83%,8 cases died within 3 years of treatment,and the survival rate for more than 3 years was 91.67%;objective response rate(ORR)in the observation group was 48.33%,compared with 41.67%in the control group,the difference was not statistically significant(P>0.05);the rates of adverse prognostic reactions of the observation group including gradeⅠ+Ⅱbone marrow suppression,gastrointestinal reactions and gradeⅠ~Ⅳrenal toxicity were lower than those of the control group(P<0.05).【Conclusion】DDP+E-ADM or TAX+DDP preoperative chemotherapy before cervical cancer resection has the same curative effect,but the overall prognosis of DDP+E-ADM is better.
作者
张丽
ZHANG Li(Department of Obstetrics and Gynecology,The Third Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan 450000,China)
出处
《中国医学工程》
2021年第10期59-62,共4页
China Medical Engineering
关键词
宫颈癌
宫颈癌切除术
顺铂
表阿霉素
预后
cervical cancer
cervical cancer resection
cisplatin
epirubicin
prognosis
